CA2234641A1 - Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases - Google Patents

Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases Download PDF

Info

Publication number
CA2234641A1
CA2234641A1 CA002234641A CA2234641A CA2234641A1 CA 2234641 A1 CA2234641 A1 CA 2234641A1 CA 002234641 A CA002234641 A CA 002234641A CA 2234641 A CA2234641 A CA 2234641A CA 2234641 A1 CA2234641 A1 CA 2234641A1
Authority
CA
Canada
Prior art keywords
aryl
phenyl
group
hydrogen
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002234641A
Other languages
English (en)
French (fr)
Inventor
Charles G. Caldwell
William K. Hagmann
Malcolm Maccoss
Shrenik K. Shah
Kothandaraman Shankaran
Karla L. Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605162.8A external-priority patent/GB9605162D0/en
Priority claimed from GBGB9605700.5A external-priority patent/GB9605700D0/en
Application filed by Individual filed Critical Individual
Publication of CA2234641A1 publication Critical patent/CA2234641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002234641A 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases Abandoned CA2234641A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US717295P 1995-11-01 1995-11-01
US60/007,172 1995-11-01
US901295P 1995-12-21 1995-12-21
US60/009,012 1995-12-21
GBGB9605162.8A GB9605162D0 (en) 1996-03-12 1996-03-12 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605162.8 1996-03-12
GBGB9605700.5A GB9605700D0 (en) 1996-03-19 1996-03-19 Hexahydro-5-imino,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605700.5 1996-03-19
PCT/US1996/017447 WO1997016430A1 (en) 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases

Publications (1)

Publication Number Publication Date
CA2234641A1 true CA2234641A1 (en) 1997-05-09

Family

ID=27451425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234641A Abandoned CA2234641A1 (en) 1995-11-01 1996-10-28 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases

Country Status (5)

Country Link
EP (1) EP0861238A4 (de)
JP (1) JP3188715B2 (de)
AU (1) AU700078B2 (de)
CA (1) CA2234641A1 (de)
WO (1) WO1997016430A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69416848T2 (de) 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
ES2206571T3 (es) * 1995-04-20 2004-05-16 G.D. SEARLE & CO. Agentes de amidino ciclico utiles como inhibidores de la oxido nitrico sintasa.
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
EP1086108A1 (de) 1998-06-10 2001-03-28 G.D. Searle & Co. Heterobicyclisch und tricyclisch als no-synthese-inhibitoren
SE9901530D0 (sv) * 1999-04-28 1999-04-28 Astra Pharma Prod Novel compounds
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP2090578A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Arylamid-Diazepinopyrimidon-Derivate zur Behandlung von neurodegenerativen Erkrankungen verursacht durch eine abnormale GSK3-beta-Aktivität
EP2090579A1 (de) 2008-01-29 2009-08-19 Sanofi-Aventis Substituierte Heteroarylamiddiazepinopyrimidon-Derivate
EP2085400A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Heteroarylamid-Oxazepinopyrimidon-Derivate
EP2085399A1 (de) 2008-01-29 2009-08-05 Sanofi-Aventis Substituierte Arylamidoxazepinopyrimidon-Derivate
EP2138498A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte trizyklische Derivate gegen neurodegenerative Erkrankungen
EP2138493A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidon-Derivate
EP2138494A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Alkylpyrimidin-4-one-Derivate
EP2138485A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte N-Oxid-Pyrazin-Derivate
EP2138488A1 (de) 2008-06-26 2009-12-30 sanofi-aventis 4-(Pyridin-4-yl)-1H-[1,3,5]Triazin-2-one-Verbindungen als GSK3-beta Hemmer zur Behandlung neurodegenerative Erkrankungen
EP2138495A1 (de) 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
EP2138492A1 (de) 2008-06-26 2009-12-30 Sanofi-Aventis Substituierte Pyrimidin-4-one-Derivate
US11325891B2 (en) * 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
AT278805B (de) * 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
ES436126A1 (es) * 1974-11-29 1977-04-01 Sandoz Ag Un procedimiento para la produccion de derivados de 2, 3-di-hidro-1h-1, 4 diazepina.
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
DE69416848T2 (de) * 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
AU700078B2 (en) 1998-12-17
JPH11501327A (ja) 1999-02-02
EP0861238A1 (de) 1998-09-02
EP0861238A4 (de) 2000-03-01
JP3188715B2 (ja) 2001-07-16
WO1997016430A1 (en) 1997-05-09
AU7528796A (en) 1997-05-22

Similar Documents

Publication Publication Date Title
US6372733B1 (en) Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
CA2234641A1 (en) Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US5629322A (en) Cyclic amidine analogs as inhibitors of nitric oxide synthase
EP0054951B1 (de) Dibenzo(b,f)(1,4)oxazepin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
Srivastava et al. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents
KR100305989B1 (ko) 파르네실-단백질트랜스퍼라제의억제제및이를포함하는약제학적조성물
WO1996014842A1 (en) Substituted heterocycles as inhibitors of nitric oxide synthase
EP2252596B1 (de) Cystein- und cystinprodrugs zur behandlung von schizophrenie und zur verminderung von drogensucht
JP4637584B2 (ja) 新規なラクタムおよびその使用
WO2008079836A2 (en) Macrocyclic factor viia inhibitors useful as anticoagulants
EP2374454B1 (de) Hemiasterlin-derivate und deren verwendung in der behandlung von krebs
CA2097465A1 (en) Pyrazinoindoles
US7351721B2 (en) Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
CA2721433A1 (en) Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
CA2218360A1 (en) Nitric oxide synthase inhibitors derived from cyclic amidines
EP1664088A2 (de) Hemiasterlin-derivate und deren verwendung
IE840927L (en) 1,5-benzothiazepines
JP2005504771A (ja) 抗腫瘍・抗癌剤としてのピペラジノン化合物と処置方法
AU2002332640A1 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2001055118A1 (fr) Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs
NZ258889A (en) 3-alkylamino-1,5-benzoxazepin- (and benzothiazepin-) 4-one derivatives and pharmaceutical compositions
HU208420B (en) Process for producing compounds with analgesic activity for the central nerve systhem and process for producing pharmaceutical activity containing them
GB2065105A (en) Dibenzazepines
GB2307911A (en) Substituted saturated aza heterocycle inhibitors of nitric oxide synthase
CA2203681A1 (en) Cyclic amidine analogs as inhibitors of nitric oxide synthase

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead